Skip to main content

How a broken cellular “GPS” leads to blood cancer development

November 20, 2026

Blood stem cells, in order to differentiate into all the types of blood cells in the body, rely on proteins known as transcription factors to switch genes on and off. In myelodysplastic syndrome (MDS), a group of blood disorders that can progress to leukemia, blood stem cell differentiation goes awry, disrupting normal blood cell development. Until recently, the mechanisms underlying this disruption remained unclear, but new research from former Damon Runyon Clinical Investigator Aaron D. Viny, MD, illuminates the problem.

Dr. Viny likens the transcription factor GATA1 to a driver navigating the genome, looking for the right genes to activate, and a protein called STAG2 to its GPS system, directing GATA1 where it needs to go. When STAG2 is mutated (as it is in at least eleven types of cancer), the GPS system goes down, and GATA1 no longer has a map to reach its intended destination. As a result, it either takes a long, inefficient route, or it goes to the wrong place and activates the wrong set of genes, leading to changes in cellular identity.

This finding is novel not only for its elucidation of blood cancer development, but because it points to a new understanding of how mutations can lead to cancer more broadly.

“As opposed to our current understanding of drivers of cancer, where the DNA ‘instructions’ are wrong, here the instructions aren’t wrong—the directions are,” explains Dr. Viny. “GATA1 knows what genes it’s meant to activate, but without STAG2, the genomic GPS is unreliable, leading to misdelivery and inefficiency. Using this framework, we can apply genetic and chemical testing to act as ‘detour signs’ to get the cells back on track.”

Given the frequency of STAG2 mutations across cancer types, such interventions could prove useful not only for leukemia patients but for other patient populations as well.

This research was published in Blood.

Share